Dr. Gerhard Waltl takes the lead of the Pharmaceutical division
Bucharest, July 11, 2017 ─ Starting with mid-June, 2017, the Pharmaceutical division of Bayer Romania has a new leadership, following the appointment of Dr. Gerhard Waltl as Country Commercial Lead.
Dr. Waltl took over this position from Mr. Panagiotis Alekos, who is now acting on a similar role in the Czech and Slovakian markets.
„It is with great pride I join the Pharmaceutical division team in Romania, as this is not only the field I have a deep expertise in, but one that is very close to Bayer’s promise of using science to create a better life. Innovation is the beating heart of our company. What drives us forward is the research and development component – creating new molecules to help people live their lives to the fullest. I am confident that we will succeed in reaching our business goals and continue being one step ahead of the modern world challenges“, stated Dr. Waltl.
A graduate of the Ludwig-Maximilian University in Munich, Dr. Gerhard Waltl has over three decades of experience in the pharmaceuticals field at international level, doubled by deep competences in marketing and management for global projects, completed by an economic university degree.
Part of the Bayer team since 1983, in various positions within the company, Dr. Waltl proved his abilities in leading both global complex team as well as local enthities in several European countries. Recently, he took over tasks in the fields of compliance, data privacy and optimizing organsational set-up of regional business representation.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com
Note to editors:
Print-quality photos can be downloaded from our website at www.news.bayer.com
TV and multimedia editors can download or order updated film footage about Bayer free of charge at www.tv-footage.bayer.com
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.